Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1991 Jul;33(3-4):310-3.
doi: 10.1007/BF01986578.

Effect of etodolac, a new nonsteroidal anti-inflammatory drug, in MRL/lpr mice with articular lesions

H Yoshida-Suzuka  1 , Y Nakamura, Y Shibata, K Kimura
Affiliations

Effect of etodolac, a new nonsteroidal anti-inflammatory drug, in MRL/lpr mice with articular lesions

H Yoshida-Suzuka et al. Agents Actions. 1991 Jul.

Abstract

Etodolac, a new nonsteroidal anti-inflammatory drug, was administered orally at doses of 1 and 5 mg/kg to MRL/MpJ-lpr/lpr (MRL/lpr) mice, and its effect on articular lesions was compared with that of indomethacin. Both etodolac and indomethacin significantly reduced swelling of the hind paw. Histopathological examination showed that etodolac significantly reduced cartilage and bone damage, whereas indomethacin treatment did not achieve a statistically significant effect. Rheumatoid factors were not affected by either etodolac or indomethacin. These results indicate that etodolac delays the development of arthritis in MRL/lpr mice, and reduces cartilage and bone damage.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. J Pharmacol Exp Ther. 1982 Feb;220(2):417-26 - PubMed
    1. Immunopharmacology. 1985 Aug;10 (1):51-60 - PubMed
    1. J Exp Med. 1978 Nov 1;148(5):1198-215 - PubMed
    1. Agents Actions. 1984 Feb;14(2):257-64 - PubMed
    1. Clin Orthop Relat Res. 1984 Jan-Feb;(182):14-23 - PubMed

LinkOut - more resources